Find A Clinical Trial
LIST OF CLINICAL TRIALS THAT ARE CURRENTLY RECRUITING PARTICIPANTS
Updated as of July 18, 2024
| Study Title | Topic/ Specialty |
|---|---|
| A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprost inil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension | Rheumatology |
| An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension | Rheumatology |
| A phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthritis, PAREXEL number 256442. | Rheumatology |
| Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia | Rheumatology |
| A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | Rheumatology |
| A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | Rheumatology |
| An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V | Rheumatology |
| A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (IP) had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) | Hematology |
| An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | Hematology |
| A Three-Arm, Randomized, Placebo‑Controlled, Double‑Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephureâ Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum | Gastroenterology |
| A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | Oncology |
| Postmarketing Safety Experience Of Edoxaban For The Prevention Of Stroke And Systemic Embolism In Adult Patients With Nonvalvular Atrial Fibrillation (NVAF) | Cardiology |
| Post-marketing observational study on safety and efficacy of Omidenepag isopropyl (EYBELIS) ophthalmic solution in Filipino patients with glaucoma or ocular hypertension | Ophthalmology |
| A Phase 3 Study to Evaluate Cefepime-taniborbactam compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP) | Infectious Disease |
| A multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison trial to investigate the efficacy and safety of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia | Psychiatry |